The effects of selenium supplementation in diabetic hemodialysis patients

The effects of selenium supplementation on carotid intima-media thickness and metabolic profiles in diabetic hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N47

Enrollment

Registered

2019-01-26

Start date

2018-12-11

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis. Chronic kidney disease (CKD)

Interventions

Intervention 1: Intervention group: Selenium supplements (Nature, California, USA), 200 µg, daily, for 24 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), daily, for

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Diabetic hemodialysis patients patients aged 18 to 80 years.

Exclusion criteria

Exclusion criteria: Patients taking antioxidant and/or anti-inflammatory supplements within 3 months prior to intervention Patients with infectious diseases Patients with malignant diseases

Design outcomes

Primary

Measure	Time frame
Mean left carotid intima-media thickness (CIMT). Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Maximum left CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Mean right carotid CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Maximum right CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.	—

Measure

Time frame

Mean left carotid intima-media thickness (CIMT). Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Maximum left CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Mean right carotid CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Maximum right CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.

—

Secondary

Measure	Time frame
Triglycerides. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Calculation using HOMA formula.	—

Measure

Time frame

Triglycerides. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Calculation using HOMA formula.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 20, 2026